Article Text

Download PDFPDF
Large proximal gastric GIST tumours: downsizing by imatinib and subsequent endoresection
  1. Ayimukedisi Yalikong1,
  2. Baohui Song1,
  3. Dongli He2,
  4. Enpan Xu1,
  5. Zhipeng Qi1,3,
  6. Yunshi Zhong1,3,4
  1. 1Endoscopy Center and Endoscopy Research Institute, Zhongshan Hospital Fudan University, Shanghai, China
  2. 2Shanghai Xuhui Central Hospital, Shanghai, China
  3. 3Zhongshan Hospital Fudan University, Shanghai, China
  4. 4Shanghai Geriatric Medical Center, Shanghai, China
  1. Correspondence to Dr Yunshi Zhong; zhong.yunshi{at}zs-hospital.sh.cn; Dr Zhipeng Qi; qi.zhipeng{at}zs-hospital.sh.cn

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Message

Surgical removal is recommended for gastrointestinal stromal tumours (GISTs) larger than 3 cm due to their potential for malignancy but limited wedge resection is not possible in the proximal stomach. Endoscopic removal of larger lesions has been technically limited in complex anatomical regions such as cardia. We report two cases of large proximal (cardia/fundus) GIST tumours (51 and 60 mm) which were downsized (to 26 and 36 mm) by 3–7 months of imatinib therapy followed by transmural endoscopic resection. Follow-up of 23 and 16 months including endoscopy and CT was unremarkable.

In more detail

GISTs commonly occur in the stomach.1 2 Due to their malignant potential, surgery is generally recommended.3–5 Recently, endoscopic resection of submucosal tumours (SMTs) has made significant progress.6 The European Society of Gastrointestinal Endoscopy recommended endoscopic resection for gastric GISTs<35 mm projecting into the lumen.3 Endoscopic full-thickness resection (EFTR), an extension of submucosal dissection, has shown promising results for SMTs arising from the deep muscularis propria (MP), particularly in the gastric fundus.7 However, achieving R0 resection in GISTs>35 mm remains challenging.8 Large GISTs in anatomically complex areas such as the cardia and fundus may still necessitate surgical resection.2 Radical surgery, however, poses risks to cardia function and patient quality of life.9 Preoperative imatinib can shrink tumours, reduce mitotic activity and lower recurrence risk.9 10 The American College of Gastroenterology guidelines suggested neoadjuvant imatinib to facilitate tumour reduction in large GISTs, enhancing the feasibility of minimally invasive endoscopic resection. Hence, in this context, we explored the combination of preoperative imatinib with EFTR as a novel, minimally invasive strategy for treating large gastric GISTs. Our primary outcomes suggested this approach may be a viable alternative for GISTs in gastric anatomical complex regions.

Patient history

Case 1 was a 65-year-old woman with abdominal distension and belching for several months. Gastroscopy revealed …

View Full Text

Footnotes

  • AY, BS and DH are joint first authors.

  • AY, BS and DH contributed equally.

  • Contributors Data collection and article writing: AY, BS, DH, EX, ZQ. Critical revision of the article for important intellectual content: YZ, ZQ. Final approval of the article: AY, BS, DH, EX, ZQ, YZ.

  • Funding This work was supported by grants from Shanghai Municipal Health Commission, Collaborative Innovation Cluster Project (grant no. 2019CXJQ02), the National Natural Science Foundation of China (grant no. 82273025, 82203460) and the Science and Technology Commission Foundation of Shanghai Municipality (grant no. 22XD1402200, 22JC1403003, 23ZR1458900).

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Not commissioned; internally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.